Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022

Anne J Huiberts; Brechje de Gier; Christina E Hoeve; Hester E de Melker; Susan Jm Hahné; Radboud center; Janneke Hhm van de Wijgert; Susan van den Hof; Mirjam J Knol

doi:10.2807/1560-7917.ES.2023.28.7.2300087

Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022

Anne J Huiberts
, Brechje de Gier
, Christina E Hoeve
, Hester E de Melker
, Susan Jm Hahné
, Radboud center
, Janneke Hhm van de Wijgert
, Susan van den Hof
, Mirjam J Knol

Research output: Contribution to journal › Article › Academic › peer-review

10 Downloads (Pure)

Abstract

We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18-59-year-olds and 14% in 60-85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.

Original language	English
Journal	Eurosurveillance
Volume	28
Issue number	7
DOIs	https://doi.org/10.2807/1560-7917.ES.2023.28.7.2300087
Publication status	Published - 16 Feb 2023

Keywords

COVID-19
SARS-CoV-2
vaccine effectiveness

Access to Document

10.2807/1560-7917.ES.2023.28.7.2300087Licence: CC BY

eurosurv-28-7-1Final published version, 279 KBLicence: CC BY

Cite this

@article{ce9c4d22f6c343fcb6c298f62d2e38ba,

title = "Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022",

abstract = "We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31\% in 18-59-year-olds and 14\% in 60-85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.",

keywords = "COVID-19, SARS-CoV-2, vaccine effectiveness",

author = "Huiberts, \{Anne J\} and \{de Gier\}, Brechje and Hoeve, \{Christina E\} and \{de Melker\}, \{Hester E\} and Hahn{\'e}, \{Susan Jm\} and Radboud center and \{van de Wijgert\}, \{Janneke Hhm\} and \{van den Hof\}, Susan and Knol, \{Mirjam J\}",

year = "2023",

month = feb,

day = "16",

doi = "10.2807/1560-7917.ES.2023.28.7.2300087",

language = "English",

volume = "28",

journal = "Eurosurveillance",

issn = "1560-7917",

publisher = "Centre Europeen pour la Surveillance Epidemiologique du SIDA",

number = "7",

}

TY - JOUR

T1 - Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022

AU - Huiberts, Anne J

AU - de Gier, Brechje

AU - Hoeve, Christina E

AU - de Melker, Hester E

AU - Hahné, Susan Jm

AU - center, Radboud

AU - van de Wijgert, Janneke Hhm

AU - van den Hof, Susan

AU - Knol, Mirjam J

PY - 2023/2/16

Y1 - 2023/2/16

N2 - We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18-59-year-olds and 14% in 60-85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.

AB - We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18-59-year-olds and 14% in 60-85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.

KW - COVID-19

KW - SARS-CoV-2

KW - vaccine effectiveness

UR - https://www.scopus.com/pages/publications/85148307069

U2 - 10.2807/1560-7917.ES.2023.28.7.2300087

DO - 10.2807/1560-7917.ES.2023.28.7.2300087

M3 - Article

C2 - 36795500

SN - 1560-7917

VL - 28

JO - Eurosurveillance

JF - Eurosurveillance

IS - 7

ER -

Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this